Literature DB >> 15763325

What determines the natural history of recurrent hepatitis C after liver transplantation?

Marina Berenguer1.   

Abstract

Mesh：

Year:  2005        PMID： 15763325     DOI： 10.1016/j.jhep.2005.01.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  24 in total

1.  [Sequelae of organ transplantation].

Authors:  S Ciesek; M Manns; C Strassburg
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

2.  Hepatitis C and liver transplantation.

Authors:  G Tsoulfas; I Goulis; D Giakoustidis; E Akriviadis; P Agorastou; G Imvrios; V Papanikolaou
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 3.  Living donor liver transplantation to patients with hepatitis C virus cirrhosis.

Authors:  Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 4.  Living donor liver transplantation for hepatitis C.

Authors:  Yasutsugu Takada; Shinji Uemoto
Journal:  Surg Today       Date:  2012-10-06       Impact factor: 2.549

Review 5.  Major challenges limiting liver transplantation in the United States.

Authors:  J A Wertheim; H Petrowsky; S Saab; J W Kupiec-Weglinski; R W Busuttil
Journal:  Am J Transplant       Date:  2011-06-14       Impact factor: 8.086

Review 6.  Corticosteroid-free strategies in liver transplantation.

Authors:  John G O'Grady
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

Authors:  Gregory T Everson; Norah A Terrault; Anna S Lok; Del R Rodrigo; Robert S Brown; Sammy Saab; Mitchell L Shiffman; Abdullah M S Al-Osaimi; Laura M Kulik; Brenda W Gillespie; James E Everhart
Journal:  Hepatology       Date:  2013-01-17       Impact factor: 17.425

8.  Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.

Authors:  Jagpreet Chhatwal; Sumeyye Samur; Emily D Bethea; Turgay Ayer; Fasiha Kanwal; Chin Hur; Mark S Roberts; Norah Terrault; Raymond T Chung
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

9.  Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.

Authors:  M G Bowring; L M Kucirka; A B Massie; X Luo; A Cameron; M Sulkowski; K Rakestraw; A Gurakar; I Kuo; D L Segev; C M Durand
Journal:  Am J Transplant       Date:  2016-08-24       Impact factor: 8.086

10.  Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

Authors:  Ainhoa Fernández-Yunquera; Cristina Ripoll; Rafael Bañares; Marta Puerto; Diego Rincón; Ismael Yepes; Vega Catalina; Magdalena Salcedo
Journal:  World J Transplant       Date:  2014-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.